WVE · Wave Life Sciences Ltd.

Wave Life Sciences is advancing its previously announced plan to redomicile its parent company from Singapore to the United States via a Scheme of Arrangement under Section 210 of Singapore's Companies Act 1967. The company applied to the Singapore High Court on April 16, 2026, for permission to hold a shareholder meeting, with the hearing scheduled for April 29, 2026. This procedural step is critical as it precedes the shareholder vote required for approval. Deadlines for objections and submissions are tight, with affidavits due April 22 and written materials by April 24, signaling momentum toward potential completion. For investors, successful redomiciliation to a Delaware corporation could simplify governance, enhance US market alignment, and affect tax or regulatory dynamics, though subject to approvals and other conditions. Court directions and filings are accessible on the company's Investor Relations website.